ArticleScientific reports2025
Enhancement and optimization of a graphene-based biosensing platform using machine learning for precise breast cancer detection.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we introduce a machine learning optimized graphene-based biosensor tailored for the early and accurate detection of breast cancer, aiming to elevate diagnostic reliability and clinical efficacy. The device employs a multilayer Ag-SiO₂-Ag architecture to amplify optical response, achieving a peak sensitivity of 1785 nm/RIU. Machine learning models are used to optimize structural parameters, enabling systematic refinement of detection accuracy and reproducibility. The optimized design demonstrates superior sensitivity compared with conventional biosensor configurations, underscoring its effectiveness in bioanalytical applications. The proposed platform offers a precise and robust solution for breast cancer screening and monitoring, with strong potential for clinical translation. To further refine sensor efficacy, a comprehensive parametric optimization approach is employed, strategically enhancing its sensitivity metrics. The sensor's heightened precision and responsiveness position it as a promising tool in biomedical diagnostics, particularly for early-stage breast cancer screening and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.